Sunshine Capital Lease Obligations from 2010 to 2025
| SBFMW Stock | USD 0.20 0.02 9.09% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 756.4 K | Current Value 476.6 K | Quarterly Volatility 287.9 K |
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
Sunshine | Capital Lease Obligations |
Latest Sunshine Biopharma's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Sunshine Biopharma Warrant over the last few years. Sunshine Biopharma capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Sunshine Biopharma asset purchases. For example, Sunshine Biopharma can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Sunshine Biopharma control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Sunshine Biopharma's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Sunshine Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 158,309 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 181.86 | |
| Mean Deviation | 237,463 | |
| Median | 0.00 | |
| Standard Deviation | 287,903 | |
| Sample Variance | 82.9B | |
| Range | 756.4K | |
| R-Value | 0.73 | |
| Mean Square Error | 41.5B | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 44,114 | |
| Total Sum of Squares | 1.2T |
Sunshine Capital Lease Obligations History
About Sunshine Biopharma Financial Statements
Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 756.4 K | 476.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.